The Cancer Prevention and Research Institute of Texas (CPRIT) awarded the University of Texas MD Anderson Cancer Center nearly $23 million in support of 20 cancer research projects to advance new breakthroughs in discovery, translational, clinical, and prevention science. In addition, CPRIT awarded $2 million for the recruitment of one first-time, tenure-track faculty member..

德克萨斯州癌症预防与研究所 (CPRIT) 向德克萨斯大学 MD 安德森癌症中心授予了近 2300 万美元，用于支持 20 个癌症研究项目，以推动在发现、转化、临床和预防科学领域的新突破。此外，CPRIT 还拨款 200 万美元用于招募一名首次任职的终身轨教职人员。

“We sincerely appreciate CPRIT’s continued funding of impactful cancer research that will help us achieve our mission to end cancer,” said Giulio Draetta, MD, PhD, CSO, MD Anderson. “This critical support allows our world-class scientists and clinicians to enhance our understanding of cancer biology and to develop strategies to better prevent, diagnose, and treat the disease, improving the lives of patients and their families.”.

“我们真诚感谢CPRIT持续资助具有影响力的癌症研究，这将有助于我们实现终结癌症的使命，”MD安德森癌症中心首席科学官朱利奥·德拉埃塔（Giulio Draetta）博士表示。“这一关键支持使我们世界一流的科学家和临床医生能够加深对癌症生物学的理解，并制定更好的策略来预防、诊断和治疗疾病，从而改善患者及其家人的生活。”

Giulio Draetta, MD, PhD, CSO, MD Anderson

朱利奥·德拉埃塔，医学博士，哲学博士，首席科学官，MD安德森

Grants for $3.7 billion for cancer research

37亿美元的癌症研究资助

Since its inception, CPRIT has awarded over $3.7 billion in grants for cancer research. MD Anderson investigators have received more than $675 million all told, approximately 18% of the total awards. Programs supported by CPRIT funding have brought more than 324 distinguished cancer researchers to Texas, advanced the knowledge base for cancer treatment throughout the state, and provided more than 10.1 million cancer prevention and early detection services reaching all 254 counties in Texas..

自成立以来，CPRIT已授予超过37亿美元的癌症研究资助。MD安德森的研究人员总共获得了超过6.75亿美元，约占总奖项的18%。由CPRIT资金支持的项目已经吸引了324多位杰出的癌症研究人员来到德克萨斯州，推动了全州癌症治疗的知识基础，并提供了超过1010万次癌症预防和早期检测服务，覆盖了德克萨斯州全部254个县。

Academic research awards to MD Anderson include:

学术研究奖项颁发给MD安德森，包括：

Leveraging synthetic and collateral lethality in MTAP loss tumors (

利用合成和附带致死性在MTAP缺失肿瘤中 (

Jordi Rodon Ahnert, MD, PhD

胡安·罗东·阿内尔特，医学博士，哲学博士

, Investigational Cancer Therapeutics)— $1,599,783

，调查性癌症治疗）——1,599,783美元

Randomized clinical trial evaluating fecal microbiota transplant in chimeric antigen receptor therapy for reversing antimicrobial-associated dysbiosis (

随机临床试验评估粪便微生物移植在嵌合抗原受体疗法中逆转抗菌药物相关菌群失调的作用 (

Neeraj Saini, MD

尼拉杰·萨伊尼，医学博士

, Stem Cell Transplantation and Cellular Therapy)—$1,598,410

，干细胞移植和细胞治疗）——1,598,410美元

Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer (

血清游离DNA甲基化和放射组学特征用于HPV相关口咽癌初始治疗后复发的早期检测 (

Jia Wu, PhD

贾武，博士

, Imaging Physics)—$1,200,000

，影像物理学）——1,200,000美元

Cancer-related fatigue and its biological contributors in adolescent and young adult brain tumor survivors: Effects of a tele-exercise intervention (

癌症相关疲劳及其生物学因素在青少年和年轻成人脑肿瘤幸存者中的影响：远程运动干预的效果 (

Maria Swartz, PhD

玛丽亚·施瓦茨，博士

, Pediatrics)— $1,199,756

，儿科）——1,199,756美元

Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer (

开发一种共享决策工具，以促进释放左炔诺孕酮的宫内系统用于子宫内膜癌的一级预防 (

Larissa Meyer, MD

拉里萨·迈耶，医学博士

, Gynecologic Oncology and Reproductive Medicine)—$1,199,542

，妇科肿瘤学和生殖医学）——1,199,542美元

Blood-based biomarkers to guide clinical decision-making with indeterminate pulmonary nodules (

基于血液的生物标志物指导不确定肺结节的临床决策 (

Edwin Ostrin, MD, PhD

埃德温·奥斯特林，医学博士，哲学博士

, General Internal Medicine)—$1,169,776

，普通内科）——1,169,776美元

Dissecting mechanisms of resistance to immune checkpoint blockade in non-small cell lung cancer (NSCLC) through the interplay of molecular and spatial architecture (

通过分子和空间结构的相互作用，剖析非小细胞肺癌（NSCLC）对免疫检查点阻断耐药的机制

Natalie Vokes, MD

娜塔莉·沃克斯，医学博士

, Thoracic–Head & Neck Medical Oncology)—$1,049,033

，胸部-头颈肿瘤内科）——1,049,033美元

MALAT1 protects against osteoporosis and bone metastasis (

MALAT1保护免受骨质疏松和骨转移的影响 (

Li Ma, PhD

李马，博士

, Experimental Radiation Oncology)—$900,000

，实验放射肿瘤学）——90万美元

Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant NSCLC (

HER2突变型非小细胞肺癌（NSCLC）中对酪氨酸激酶抑制剂（TKIs）和抗体药物偶联物（ADCs）的耐药机制 (

John Heymach, MD, PhD

约翰·海马赫，医学博士，哲学博士

, Thoracic–Head & Neck Medical Oncology)—$900,000

，胸部-头颈肿瘤内科）——90万美元

Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETs (

创新的体外和体内患者来源的癌症模型，以推进G1/G2 GEP-NETs的精准医学

James Yao, MD

姚詹姆斯，医学博士

, Gastrointestinal Medical Oncology)— $900,000

，胃肠道肿瘤内科）——90万美元

Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma (

新辅助联合抗PD-L1和抗TIGIT免疫检查点阻断在口腔鳞状细胞癌中的应用 (

Maura Gillison, MD, PhD

毛拉·吉利森，医学博士，哲学博士

, Thoracic–Head & Neck Medical Oncology)—$899,998

，胸部-头颈医学肿瘤学）——899,998美元

KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC (

KRAS抑制剂在非小细胞肺癌（NSCLC）中引发的适应性耐药机制和免疫抑制

Don Gibbons, MD, PhD

唐·吉本斯，医学博士，哲学博士

, Thoracic–Head & Neck Medical Oncology)—$899,997

，胸部-头颈医学肿瘤学）——899,997美元

Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer (

TRIP13和Aurora A在Rb缺陷型癌症中的合成致死性 (

Faye Johnson, MD, PhD

费伊·约翰逊，医学博士，哲学博士

, Thoracic–Head & Neck Medical Oncology)—$899,994

，胸部-头颈医学肿瘤学）——899,994美元

Understanding and overcoming resistance of SMARCA4-mutant lung cancers to immunotherapy (

理解并克服SMARCA4突变型肺癌对免疫疗法的抵抗性 (

Yonathan Lissanu, MD, PhD

约纳坦·利桑努，医学博士，哲学博士

, Thoracic and Cardiovascular Surgery)— $899,991

，胸外科和心血管外科）——899,991美元

Deciphering and targeting age-related metastatic competence of the omentum (

破解和靶向网膜的年龄相关性转移能力 (

Honami Naora, PhD

野浪穂奈美，博士

, Molecular and Cellular Oncology)—$899,984

，分子与细胞肿瘤学）——899,984美元

Clonal hematopoiesis and toxicity from radiation therapy (Kevin Nead, MD, Epidemiology)—$899,885

克隆性造血和放疗毒性（Kevin Nead，医学博士，流行病学）— 899,885美元

Improving detection of hepatocellular carcinoma in non-cirrhotic metabolic dysfunction associated steatohepatitis (MASLD) patients (

改善非肝硬化代谢功能障碍相关脂肪性肝炎（MASLD）患者中肝细胞癌的检测

David Fuentes, PhD

大卫·富恩特斯，博士

, Imaging Physics)—$899,808

，影像物理学）——899,808美元

Engineering second-generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy (

工程化第二代体内嵌合抗原受体巨噬细胞（CARMs）用于胶质母细胞瘤治疗

Wen Jiang, MD, PhD

姜文，医学博士，哲学博士

, Radiation Oncology)—$898,263

，放射肿瘤学）——898,263美元

Exploiting synthetic lethalities between HNRNPK loss and ribosomal dysfunction in del9q AML (

利用HNRNPK缺失与del9q AML中核糖体功能障碍之间的合成致死性

Sean Post, PhD

肖恩·波斯特，博士

, Leukemia)—$896,322

，白血病）——896,322美元

HSP90 capacitance: Discovery of a new mechanism driving evolution of drug resistance in head and neck squamous cell carcinoma (

HSP90电容：发现驱动头颈部鳞状细胞癌药物抵抗进化的新机制 (

Georgios Karras, PhD

乔治·卡拉拉斯，博士

, Genetics)—$890,201

，遗传学）——890,201美元

News

新闻